SANTA CRUZ BIOTECHNOLOGY, INC.

Bcl10 (1-197): sc-4408 WB

SANTA CRUZ BIOTECHNOLOGY

The Power to Question

BACKGROUND

Bcl10, also designated CIPER, c-CARMEN and mE10, was first identified as a gene truncated or mutated in MALT B cell lymphomas and other tumor types. Bcl10 is homologous to the equine herpesvirus-2 E10 gene, and like E10 it contains an amino-terminal caspase recruitment domain (CARD). Expression of Bcl10 was shown to induce NFκB activation in a NIK-dependent pathway, and the CARD domain was shown to be essential for this activation. In a separate study, Bcl10 by itself did not induce JNK or NFκB activation. Overexpression of Bcl10 was shown to induce apoptosis, in a manner that was dependent on CARD-mediated oligomerization. Bcl10 was also shown to play a role in processing of caspase-9 to its active dimer. Other studies have shown that Bcl10 is not mutated in many human tumors and lymphomas.

REFERENCES

1. Willis, T.G., Jadayel, D.M., Du, M.Q., Peng, H., Perry, A.R., Abdul-Rauf, M., Price, H., Karran, L., Majekodunmi, O., Wlodarska, I., Pan, L., Crook, T., Hamoudi, R., Isaacson, P.G., and Dyer, M.J. 1999. Bcl10 is involved in t(1;14)(p22;q32) of MALT B cell lymphoma and mutated in multiple tumor types. Cell 96: 35-45.
2. Koseki, T., Inohara, N., Chen, S., Carrio, R., Merino, J., Hottiger, M.O., Nabel, G.J., and Nunez, G. 1999. CIPER, a novel NFκB-activating protein containing a caspase recruitment domain with homology to Herpesvirus-2 protein E10. J. Biol. Chem. 274: 9955-9961.
3. Thome, M., Martinon, F., Hofmann, K., Rubio, V., Steiner, V., Schneider, P., Mattmann, C., and Tschopp, J. 1999. Equine herpesvirus-2 E10 gene product, but not its cellular homologue, activates NFκB transcription factor and c-Jun N-terminal kinase. J. Biol. Chem. 274: 9962-9968.
4. Yan, M., Lee, J., Schilbach, S., Goddard, A., and Dixit, V. 1999. mE10, a novel caspase recruitment domain-containing proapoptotic molecule. J. Biol. Chem. 274: 10287-10292.
5. Fakruddin, J.M., Chaganti, R.S., and Murty, V.V. 1999. Lack of Bcl10 mutations in germ cell tumors and B cell lymphomas. Cell 97: 683-684.
6. Apostolou, S., De Rienzo, A., Murthy, S.S., Jhanwar S.C., and Testa, J.R. 1999. Absence of Bcl10 mutations in human malignant mesothelioma. Cell 97: 684-686.7. Fischer, K.D., et al. 2004. New roles for Bcl10 in B-cell development and LPS response. Trends Immunol 25: 113-116.
7. Scharschmidt, E., Wegener, E., Heissmeyer, V., Rao, A., Krappmann, D. 2004. Degradation of Bcl10 induced by T-cell activation negatively regulates NFκ B signaling. Mol. Cell Biol. 24: 3860-3873.
8. Liu, Y., Dong, W., Chen, L., Xiang, R., Xiao, H., De, G., Wang, Z., Qi, Y. 2004. Bcl10 mediates lipopolysaccharide/toll-like receptor-4 signaling through interaction with Pellino2. J. Biol. Chem. 279: 37436-37444.
9 Ye, H., Gong, L., Liu, H., Hamoudi, R.A., Shirali, S., Ho, L., Chott, A., Streubel, B., et al. 2005. MALT lymphoma with t(14;18)(q32;q21)/IGH-MALT1 is characterized by strong cytoplasmic MALT1 and Bcl10 expression. J. Pathol. 205: 293-301.

SOURCE

Bcl10 (1-197) is expressed in *E. coli* as a 49 kDa tagged fusion protein corresponding to amino acids 1-197 of Bcl10 of human origin.

PRODUCT

Bcl10 (1-197) is purified from bacterial lysates (>98%) by column chromatography; supplied as 10 µg protein in 0.1 ml SDS-PAGE loading buffer.

APPLICATIONS

Bcl10 (1-197) is suitable as a Western blotting control for sc-5611 and sc-13153.

STORAGE

Store at -20° C; stable for one year from the date of shipment.

RESEARCH USE

For research use only, not for use in diagnostic procedures.